TIL - NASDAQ

Instil Bio, Inc.

TIL·NASDAQ

$8.10

-0.84%

HealthcareBiotechnology

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$54.94M

EPS-10.7000

P/E Ratio-0.76

Earnings Date08/07/2026

til

Other Current Liabilities

Last Annual Value

3.69M

3-Year CAGR

-4%

5-Year CAGR

10-Year CAGR

31%

Adjust for Inflation

Instil Bio, Inc. Competitors Analysis of Other Current Liabilities

TIL · NASDAQ

Company	Other Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Instil Bio, Inc. NASDAQ:TIL	3.69M	44.8%	-23.0%	N/A
Whitehawk Therapeutics Inc NASDAQ:WHWK	13.60M	64.0%	N/A	N/A
MacroGenics, Inc. NASDAQ:MGNX	22.23M	N/A	1.5%	22.5%
Surrozen, Inc. NASDAQ:SRZN	7.91M	200.4%	68.1%	N/A
Cognition Therapeutics, Inc. NASDAQ:CGTX	11.99M	117.5%	37.1%	N/A
Seer, Inc. NASDAQ:SEER	7.16M	38.0%	8.7%	N/A
Spero Therapeutics, Inc. NASDAQ:SPRO	5.58M	20.1%	N/A	4.2%
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	20.54M	73.9%	47.3%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	10.29M	20.3%	21.3%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	13.31M	12.4%	19.4%	N/A
Inovio Pharmaceuticals, Inc. NASDAQ:INO	36.44M	54.2%	12.0%	16.2%

Instil Bio, Inc. Fair Value Envelope

TIL · NASDAQ

Our analysis suggests that TIL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.1013, this represents a potential HIDDEN relative to our calculated worth for Instil Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.1013

Related Guides

Blog Categories

Continue your TIL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.